Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics, LLC today announced that it has entered into an exclusive license with the University of Washington for certain biologic compounds and technology developed to treat autoimmune diseases including systemic lupus erythematosus (SLE). The technology was discovered in the laboratories of Dr. Keith Elkon and Dr. Jeffrey Ledbetter of the University of Washington School of Medicine. The compounds are targeted biologic therapies engineered to inhibit the proximal steps in the interferon-alpha cascade, which appears to be chronically activated in lupus patients.

“Drs. Elkon and Ledbetter are internationally recognized scientists in the field of autoimmune diseases, whose efforts have identified RSVL-125 as a promising potential treatment to help patients suffering from lupus, a serious autoimmune disease for which few effective therapies currently exist”

Resolve Therapeutics is focused on advancing its lead compound RSLV-125 through pre-clinical IND enabling safety studies and into early clinical trials in lupus patients. "Drs. Elkon and Ledbetter are internationally recognized scientists in the field of autoimmune diseases, whose efforts have identified RSVL-125 as a promising potential treatment to help patients suffering from lupus, a serious autoimmune disease for which few effective therapies currently exist," commented James Posada, CEO of Resolve. Upon successful completion of its early clinical trials for RSLV-125, Resolve plans to partner the compound for late-stage clinical development and commercialization with one of the several pharmaceutical companies that have a strategic interest in lupus.

"By partnering with the biotechnology and pharmaceutical sector to develop new treatments for disease around UW innovations, the UW Center for Commercialization is contributing to an important and exciting dimension of the School of Medicine's mission to improve health. Resolve Therapeutics will be working diligently toward the mutual goal of helping patients with Lupus," added Linden Rhoads, Vice Provost for the University of Washington Center for Commercialization.